MEDBOTX™ represents the evolution into a broader point-of-care manufacturing platform designed for personalized medicines, peptides and advanced dose formats

Potential U.S. peptide reclassification and possible inclusion of select peptides on the Section 503A Bulks List could create a timely opportunity for MEDBOTX™ in compounding pharmacies, hospitals and personalized medicine settings
​
TORONTO, ON — May 27, 2026 — PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (“PharmaTher” or the “Company”), a pharmatech company focused on enabling personalized medicine through robotic 3D printing, today announced that it is strategically evolving its platform focus from PatchPrint™ 3D printer to MEDBOTX™, the Company’s robotic 3D printing platform designed for personalized medicines, peptides and advanced pharmaceutical dose formats.

Figure 1. Prototype of MEDBOTX™ robotic 3D printing platform

​PharmaTher believes MEDBOTX™ represents the next stage of the Company’s growth and the evolution of its work in pharmaceutical R&D, microneedle patches, and 3D printing. By expanding beyond a single-dose format such as microneedle patches, MEDBOTX™ gives PharmaTher a broader and more scalable platform for personalized, patient-specific and small-batch pharmaceutical manufacturing. The Company expects MEDBOTX™ to become the central technology platform for its product development and sales, partnerships, and strategy in personalized medicines.

“MEDBOTX™ represents the next stage of PharmaTher’s work in pharmaceutical drug development and manufacturing,” said Fabio Chianelli, Chief Executive Officer of PharmaTher. “We believe our MEDBOTX™ platform provides a focused path to participate in the growing demand for personalized medicines, particularly peptides, where flexible, small-batch and point-of-care manufacturing may become increasingly important as the U.S. evaluates potential regulatory pathways for certain peptide compounds and specialty pharmaceuticals.”

MEDBOTX™ is designed as a point-of-care and small-batch manufacturing platform that may support personalized dose forms, including polypills, tablets, oral films, gels, suppositories, chews, patches, osmotic-pump formats, and other advanced drug delivery formats. PharmaTher’s initial commercial focus is expected to include personalized medicines, regulated peptide opportunities, compounded pharmaceuticals, and partner-facing formulation and development services.

Figure 2. Potential dose formats from MEDBOTX™

MEDBOTX™ for Personalized Medicines
PharmaTher believes healthcare is moving toward greater personalization, including patient-specific dosing, alternative delivery formats, combination therapies, improved adherence and localized manufacturing. These trends are particularly relevant in settings where conventional mass manufacturing may not address the needs of specific patients, prescribers or clinical workflows.

MEDBOTX™ is designed to support this shift by enabling programmable, flexible and potentially scalable production of personalized medicines and advanced dose formats, which could be relevant for:

1. Hospitals and compounding pharmacies, including 503A pharmacies, seeking point-of-care capabilities to support individualized, prescription-based medicines;
2. PharmaTher’s internal product pipeline, including custom peptides, psychedelics, and microneedle patch development programs; and
3. Specialty pharmaceutical and biotech partners seeking formulation development and small-batch production for clinical studies and commercialization.

 
Peptides: A Timely Opportunity for MEDBOTX™
PharmaTher believes peptides represent an attractive near-term opportunity for MEDBOTX™. Peptides are an important and growing class of therapeutic compounds, but many can present formulation, stability, delivery and manufacturing challenges. These challenges may create a need for flexible manufacturing platforms capable of supporting customized dose forms, small-batch production and patient-specific formulations.

The U.S. regulatory activity involving therapeutic peptides could become an important external catalyst for MEDBOTX™. The U.S. Food and Drug Administration’s Pharmacy Compounding Advisory Committee is scheduled to meet on July 23–24, 2026, to discuss certain bulk drug substances being considered for possible inclusion on the Section 503A Bulks List, including BPC-157-related, KPV-related, TB-500-related and MOTs-C-related bulk drug substances.

If certain peptides gain a broader lawful pathway for compounding under appropriate medical supervision, PharmaTher believes MEDBOTX™ could become increasingly relevant as a platform for personalized peptide formulation development, small-batch production, and point-of-care manufacturing workflows in compound pharmacies and hospitals.

MEDBOTX™ Commercial Strategy
PharmaTher intends to focus its MEDBOTX™ commercialization strategy on platform opportunities that may include:

• System placements with compounding pharmacies, hospitals, clinics, research institutions and qualified partners;
• Consumables and formulation inputs that may support recurring revenue opportunities;
• Internal product development, including peptide and psychedelic formulations and microneedle patch programs;
• CDMO-style services for partners seeking formulation development and small-batch development; and
• Strategic collaborations involving bioprinting and bio-integrated applications, including hydrogel-based implants, tissue scaffolds, and smart wearables.

The Company expects its near-term MEDBOTX™ priorities to include advancing toward commercial launch, identifying commercial partnerships for regulated peptides and compounded pharmaceuticals, and positioning MEDBOTX™ as PharmaTher’s primary platform for personalized medicine manufacturing.

MEDBOTX™ Commercialization Milestones
The Company’s expected MEDBOTX™ commercialization milestones include:

Summer 2026: Completion of the MEDBOTX™ system for internal R&D and commercial demonstrations.

Fall 2026: Commencement of commercialization activities, including engagement with potential commercial partners, compounding pharmacy partners, hospitals, clinics, research institutions and pharmaceutical development collaborators.

Ongoing: Development of proprietary “printing recipes” for selected peptides and compounds, supported by GMP-aligned workflow software, AI-assisted formulation development, related process know-how, and new intellectual property filings to strengthen the Company’s personalized medicine and advanced manufacturing platform.

PharmaTher is currently collaborating with a bioprinting manufacturer to finalize customizations and scale up manufacturing of MEDBOTX™.

PharmaTher’s focus is clear: advance the MEDBOTX™ platform, engage commercial partners, develop proprietary formulation and manufacturing know-how, and build long-term value in the growing market for personalized medicines.

About MEDBOTX™
MEDBOTX™ is PharmaTher’s robotic 3D printing platform being developed for personalized medicines. MEDBOTX™ is designed to support point-of-care and small-batch manufacturing, including potential applications in compounding pharmacies, hospitals, clinics, research institutions, pharmaceutical partners, and PharmaTher’s development programs.
​
About PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd. (CSE: PHRM; OTCQB: PHRRF) is a specialty pharmaceutical and technology company focused on developing, acquiring and commercializing pharmaceutical products and enabling technologies. The Company is advancing MEDBOTX™, a robotic 3D printing platform designed for personalized medicine, peptides and advanced dose formats, while continuing to evaluate strategic opportunities for its ketamine portfolio, PharmaPatch™ psychedelics research, and interest in Sairiyo Therapeutics Inc. For more information, visit PharmaTher.com.
For more information about PharmaTher, please contact:
 
Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com
 
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking StatementsThis news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including, but not limited to, statements regarding the Company’s business strategy; the strategic evolution from PatchPrint™ to MEDBOTX™; the development, design, functionality, customization, validation, scalability, commercialization, deployment, adoption and potential use of MEDBOTX™; the Company’s collaboration with a bioprinting manufacturer to scale manufacturing of MEDBOTX™ systems; the expected completion of the MEDBOTX™ system for internal R&D and commercial demonstrations in Summer 2026; the expected commencement of commercialization activities in Fall 2026; the Company’s ability to engage commercial partners, compounding pharmacy partners, hospitals, clinics, research institutions and pharmaceutical development collaborators; and the potential use of MEDBOTX™ in personalized medicine, peptide formulation, compounded pharmaceuticals, point-of-care manufacturing, small-batch production, advanced dose formats, bioprinting, bio-integrated medical devices, tissue scaffolds, smart wearables and other healthcare applications.
Forward-looking statements also include statements regarding the development of proprietary “printing recipes” for selected peptides and compounds; formulation parameters; GMP-aligned workflow software; AI-assisted formulation development; related process know-how; new intellectual property filings; the Company’s internal R&D programs; potential system placements; consumables and formulation inputs; formulation R&D and CDMO-style services; licensing and co-development partnerships; and the potential for MEDBOTX™ to become PharmaTher’s central technology platform for product development, commercial partnerships and strategy in personalized medicines.
This news release also contains forward-looking statements regarding the potential U.S. regulatory reclassification of certain peptides; the possible inclusion of certain bulk drug substances on the Section 503A Bulks List; the timing, outcome, scope or impact of any FDA advisory committee meeting, public comment process, policy change or regulatory decision; and the potential relevance of BPC-157-related, KPV-related, TB-500-related, MOTs-C-related or other peptide compounds to the Company’s platform, product development, formulation, manufacturing or commercial strategy. There can be no assurance that any peptide will be included on the Section 503A Bulks List, that any regulatory change will occur, that any such change will create a lawful or commercially viable pathway for the Company, or that MEDBOTX™ will be used in connection with any specific peptide, compounded medicine or pharmaceutical product.
Forward-looking statements are often identified by words such as “believe,” “expect,” “expects,” “plan,” “plans,” “intend,” “may,” “could,” “would,” “should,” “anticipate,” “potential,” “opportunity,” “designed,” “developing,” “target,” “focus,” “strategy,” “commercialization,” “milestone,” and similar expressions. These statements are based on management’s current expectations, assumptions and beliefs as of the date of this news release and are subject to known and unknown risks, uncertainties and other factors that could cause actual results, events or achievements to differ materially from those expressed or implied by such forward-looking statements.
These risks and uncertainties include, among others, risks related to research and development; prototype design and completion; technology customization, manufacturing, scale-up, validation and performance; software development, GMP-aligned workflow integration and AI-assisted formulation development; formulation feasibility; intellectual property protection; the development and reproducibility of “printing recipes”; regulatory requirements applicable to medical, pharmaceutical, compounding, manufacturing, software, quality system and point-of-care production activities; the availability and cost of financing; the ability to attract and retain commercial partners; market acceptance; competition; changes in applicable laws, regulations, guidance or policy; the outcome of FDA or other regulatory reviews; supply chain constraints; reliance on third-party manufacturers, collaborators and service providers; and general economic, industry and capital market conditions.
There can be no assurance that MEDBOTX™ will be successfully developed, completed, validated, manufactured, commercialized, deployed or adopted; that the Company will meet its expected development or commercialization timelines; that any commercial partnerships, system placements, licensing arrangements, CDMO-style services, consumables revenue, formulation programs, intellectual property filings or other business opportunities will be completed or generate revenue; that any peptide-related regulatory development will occur or benefit the Company; or that any product, formulation, software, manufacturing process or technology described herein will receive regulatory approval, comply with applicable regulatory requirements or achieve commercial success. The product candidates, technologies, software, formulations, manufacturing processes and applications described in this news release are investigational, developmental or conceptual in nature and have not been approved by the U.S. Food and Drug Administration, Health Canada or any other regulatory authority. Safety, efficacy, quality, manufacturing suitability, regulatory compliance and commercial feasibility have not been established.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. Except as required by applicable law, PharmaTher undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additional risk factors are described in the Company’s continuous disclosure filings available under the Company’s profile on SEDAR+.
This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

Independent research identified cepharanthine as a potential Hantavirus entry inhibitor, supporting further evaluation of Sairiyo’s patented, orally bioavailable PD-001 cepharanthine formulation for Hantavirus
​
TORONTO, ON — May 13, 2026 — PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (“PharmaTher” or the “Company”), a specialty pharmaceutical company, today announced that Sairiyo Therapeutics Inc. (“Sairiyo”), a company 49% owned by PharmaTher and 51% owned by PharmaDrug Inc. (CSE: PHRX) (OTC: LMLLF), is pursuing its strategic plans to focus on the clinical development of its patented enteric-coated oral Cepharanthine (“PD-001”) as a potential therapeutic candidate for Hantavirus (“HTNV”).

Independent published research has identified cepharanthine as a potential Hantavirus entry inhibitor. In the study titled Screening and identification of HTNVpv entry inhibitors with high-throughput pseudovirus-based chemiluminescence,1 researchers developed a high-throughput screening method using Hantaan virus pseudovirus (“HTNVpv”) and evaluated a library of 1,813 approved drugs and 556 small-molecule compounds. The study identified six compounds with anti-HTNVpv activity in the low-micromolar range, including cepharanthine. Among the selected compounds, cepharanthine not only demonstrated in vitro anti-HTNVpv activity but also inhibited HTNVpv-fluc infection in Balb/c mice. In that mouse model, cepharanthine inhibited Hantavirus pseudovirus infection 5 hours after infection by approximately 94% at 180 mg/kg/day, 93% at 90 mg/kg/day, and 92% at 45 mg/kg/day, with statistical significance reported at P < 0.01. The researchers also reported that time-of-addition analysis suggested cepharanthine may act during the viral entry and membrane fusion phases, which are important early steps in the hantavirus infection cycle. The authors concluded that cepharanthine may represent a candidate for further evaluation in hantavirus-related diseases, including HFRS and hantavirus cardiopulmonary syndrome.

Hantaan virus is an Old World hantavirus associated with hemorrhagic fever with renal syndrome (“HFRS”), a potentially severe disease affecting the kidneys and blood vessels. Hantaviruses remain a global public health concern because they are rodent-borne, can cause severe illness and death, and currently have limited treatment options. According to the World Health Organization, hantavirus infections can cause severe disease, HFRS occurs primarily in Europe and Asia, and there is no licensed specific antiviral treatment for hantavirus infection, with care currently focused on supportive management of respiratory, cardiac, and kidney complications.

“This independent research provides a reasonable scientific rationale to further evaluate Sairiyo’s PD-001 as a potential antiviral candidate for Hantavirus and other hantavirus-related diseases,” said Fabio Chianelli, CEO of PharmaTher. “The published findings suggest cepharanthine may interfere with early viral entry and membrane fusion, which are critical steps in the hantavirus infection cycle. PD-001 was specifically designed to address cepharanthine’s historical limitation of poor oral bioavailability through a patented enteric-coated oral formulation.”

Sairiyo has previously received approval from an Australian Human Research Ethics Committee to initiate a first-in-human Phase 1 clinical study of PD-001 for viral infectious diseases. The planned Phase 1 study is intended to evaluate the safety, tolerability, pharmacokinetics, and bioavailability profile of PD-001 in healthy volunteers and is not designed to establish therapeutic efficacy or demonstrate that PD-001 can treat, prevent, or cure any viral infectious disease, including Hantavirus or related hantavirus indications. Any future advancement of PD-001 into further clinical studies or indication-specific development would be subject to successful completion of Phase 1 activities, additional preclinical and/or clinical data, regulatory review, availability of financing, manufacturing readiness, and other development risks. PD-001 was previously the subject of a US$3.4 million contract from the Defense Threat Reduction Agency (“DTRA”) for Ebola virus-related research2; however, this prior contract should not be interpreted as government endorsement or validation of PD-001, nor does it establish efficacy, regulatory approval, commercial viability, or the likelihood of future development success in Ebola virus, Hantavirus, or any other infectious disease indication.

The Company would like to make it clear that is not making any express or implied claim that PD-001 or cepharanthine can treat, prevent, cure, or eliminate Hantavirus, HFRS, HCPS, or any other infectious disease at this time.

About PD-001 (Enteric-coated Oral Cepharanthine)

Cepharanthine is a natural product and an approved drug used for more than 70 years in Japan to successfully treat a variety of acute and chronic diseases. In clinical research, cepharanthine has been shown to exhibit multiple pharmacological properties including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic effects3,4. However, historically cepharanthine's low oral bioavailability has represented a major obstacle to realizing its full clinical potential.

Compared to generic cepharanthine, PD-001 has been shown in rodent and non-rodent models to possess markedly improved oral bioavailability (more easily absorbed). These findings support the development of an orally administered formulation, and in so doing, removes the undesirable requirement for frequent intravenous dosing to maintain therapeutic levels of drug in circulation. Sairiyo endeavours to develop an efficacious oral therapeutic to potentially improve outcomes for infectious disease and oncology applications.
 
PD-001 is protected by US Patent US10576077, with a patent expiration date of March 23, 2036.
 
About PharmaTher Holdings Ltd.
 
PharmaTher Holdings Ltd. (OTCQB: PHRRF; CSE: PHRM) is a specialty pharmaceutical company focused on developing, acquiring, and commercializing pharmaceutical products and enabling technologies. For more information, visit PharmaTher.com.
 
For more information about PharmaTher, please contact:
 
Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com
 
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
 
Forward-Looking Statements
 
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Forward looking statements in this press release relate to the potential for cepharanthine as a treatment for Hantaan Virus and the development of the Company's business. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements.
 
Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; the actual results of the Company's future operations; competition; changes in legislation affecting the Company; the ability to obtain and maintain required permits and approvals, the timing and availability of external financing on acceptable terms; lack of qualified, skilled labour or loss of key individuals..
 
A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company’s disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
 
The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.
 
Forward-looking information contained in this press release is expressly qualified by this cautionary statement. The forward-looking information contained in this press release represents the expectations of the Company as of the date of this press release and, accordingly, are subject to change after such date. However, the Company expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
 
Sources:

1. Wen X, Zhang L, Liu Q, Xiao X, Huang W, Wang Y. Screening and identification of HTNVpv entry inhibitors with high-throughput pseudovirus-based chemiluminescence. Virol Sin. 2022 Aug;37(4):531-537. doi: 10.1016/j.virs.2022.04.015. Epub 2022 May 2. PMID: 35513270; PMCID: PMC9437608. (Link to paper)
   
2. https://www.swri.org/press-release/southwest-research-institute-texas-biomedical-research-institute-awarded-34-million
   
3. Saito T, Hikita M, Kohno K, Tanimura H, Miyahara M, Kobayashi M. Enhanced expression of the multidrug resistance gene in vindesine-resistant human esophageal cancer cells. Oncology. 1994 Sep-Oct;51(5):440-5. doi: 10.1159/000227380. PMID: 8052486.
   
4. Zhou P, Zhang R, Wang Y, Xu D, Zhang L, Qin J, Su G, Feng Y, Chen H, You S, Rui W, Liu H, Chen S, Chen H, Wang Y. Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals. Oncotarget. 2017 Nov 27;8(67):111144-111160. doi: 10.18632/oncotarget.22676. Erratum in: Oncotarget. 2021 Jan 05;12(1):61-62. PMID: 29340044; PMCID: PMC5762312.

Company believes supportive U.S. policy momentum may strengthen the strategic value of its ketamine patch, KetaVault™ platform, retained ketamine programs, and prior FDA-approved ketamine ANDA transaction
 
TORONTO, ON — April 21, 2026 — PharmaTher Holdings Ltd. (OTCQB: PHRRF; CSE: PHRM) (“PharmaTher” or the “Company”), a specialty pharmaceutical company, today announced that it believes the recent U.S. executive order, "Accelerating Medical Treatments for Serious Mental Illness," signed on April 18, 2026, may help create a more supportive political and regulatory backdrop for innovative ketamine-based programs, particularly where severe unmet need, depression, suicidality, and other difficult-to-treat mental health conditions are involved.
 
“We believe the recent U.S. executive order is another signal that policymakers are placing greater urgency on advancing new treatment options for serious mental illness,” said Fabio Chianelli, Chief Executive Officer of PharmaTher. “We believe this evolving regulatory environment strengthens the strategic value of our ketamine portfolio, including our microneedle patch program, KetaVault™ partnership portal, retained specialty ketamine programs, and our ongoing economic exposure from the prior sale of our FDA-approved ketamine ANDA.”
 
Supportive U.S. Policy Momentum for Serious Mental Illness
 
The executive order is focused on psychedelic drugs for serious mental illness and emphasizes accelerated research, clinical trial participation, data sharing, and real-world evidence generation, including collaboration among HHS, FDA, the Department of Veterans Affairs, and the private sector. PharmaTher believes the broader direction of U.S. policy reflects growing support for accelerating the development of important therapies for patients with severe and treatment-resistant mental health conditions. These measures could contribute to a more supportive backdrop for advancing differentiated ketamine programs, particularly in areas involving severe unmet need, mental health, and veteran-focused treatment opportunities.
 
Re-Emphasizing the Ketamine Patch Opportunity
 
PharmaTher believes its ketamine microneedle patch program could represent an important differentiated opportunity within this evolving environment. The Company has previously reported completion of an IND-enabling pharmacokinetic and tolerability study for its ketamine patch and has described the program as part of its broader effort to develop patient-friendly ketamine delivery options across mental health, neurological, and pain disorders. PharmaTher believes a patch-based approach could offer strategic lifecycle value through controlled and sustained delivery, reduced treatment burden, and broader commercial flexibility.

Figure 1. Representative image of PharmaTher’s PharmaPatch™ ketamine microneedle patch and close-up of the microneedle array.
 
FDA-Approved Ketamine Foundation Provides Ongoing Upside
 
In addition to its proprietary development programs, PharmaTher believes its prior FDA approval for its generic ketamine (ANDA #217858) remains strategically important. The Company previously sold its U.S. ketamine ANDA to a sterile-injectables pharmaceutical company and disclosed that the transaction could generate more than US$25 million over time, subject to commercial performance, including milestone and profit-sharing payments. PharmaTher believes that the transaction provides economic participation in the U.S. ketamine market while avoiding the capital requirements, inventory burden, and commercial infrastructure needed to launch a generic injectable product independently.
 
Broader Ketamine Portfolio Remains in Place
 
PharmaTher has stated that the ANDA sale did not include its broader ketamine portfolio and that the Company continues to own its ketamine-based programs for Parkinson’s disease, amyotrophic lateral sclerosis, and complex regional pain syndrome, as well as its ketamine microneedle patch program. While these neurological and pain programs are separate from the executive order’s specific focus on serious mental illness, PharmaTher believes they remain important long-term assets within its broader ketamine strategy and could continue to benefit from increasing strategic and commercial interest in differentiated ketamine development.
 
KetaVault™ Strengthens PharmaTher’s Partnership and Platform Value
 
PharmaTher believes KetaVault™ strengthens its ketamine platform by offering a proprietary portal to proprietary ketamine data (including INDs, CMC, and clinical data) for pharmaceutical, biotech, academic, and government entities. This portal could accelerate partnerships and commercial planning across mental health, neurology, pain, and other ketamine opportunities. With increasing policy focus on serious mental illness, PharmaTher believes its differentiated delivery technology, retained ketamine rights, regulatory experience, and partnership-enabling platforms such as KetaVault™ position it well to advance its ketamine programs through internal development, strategic collaborations, and regulatory engagement.
 
About PharmaTher Holdings Ltd.
 
PharmaTher Holdings Ltd. (OTCQB: PHRRF; CSE: PHRM) is a specialty pharmaceutical company focused on developing, acquiring, and commercializing pharmaceutical products and enabling technologies. For more information, visit PharmaTher.com.
 
For more information about PharmaTher, please contact:
 
Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com
 
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
 
Forward-Looking Statements
 
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. Forward-looking statements in this release include, but are not limited to, statements regarding: the potential impact, significance, interpretation, or timing of the recent U.S. executive order and related governmental or regulatory developments concerning serious mental illness; the extent to which such developments may create a supportive political, regulatory, clinical, or commercial backdrop for ketamine-based programs; the future development, regulatory pathway, differentiation, strategic value, and commercial potential of PharmaTher’s ketamine microneedle patch program and other proprietary ketamine delivery technologies; the strategic value and potential utility of KetaVault™ as a platform to support partnering, development, and commercialization opportunities; the Company’s ability to enter into strategic collaborations or other transactions relating to its ketamine programs, technologies, or data assets; the Company’s ability to derive economic benefit from the prior sale of its U.S. ketamine ANDA, including potential milestone and profit-sharing payments; the continued development, value, and strategic relevance of the Company’s ketamine-based programs for Parkinson’s disease, amyotrophic lateral sclerosis, complex regional pain syndrome, mental health, and other indications; and the Company’s ability to advance its ketamine-based programs through internal development, strategic collaborations, regulatory engagement, and other strategic initiatives. Forward-looking statements are often identified by words such as “believe,” “expect,” “plan,” “intend,” “may,” “could,” “would,” “should,” “anticipate,” “potential,” “opportunity,” and similar expressions. These statements are based on management’s current expectations, assumptions, and beliefs as of the date of this news release and are subject to known and unknown risks, uncertainties, and other factors that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: uncertainties relating to the interpretation, implementation, and effect of executive, governmental, or regulatory actions; the risk that any political or regulatory developments may not result in any direct benefit to ketamine-based products or programs; risks relating to research and development, clinical progress, regulatory review, manufacturing and supply, intellectual property protection, data access, market acceptance, competition, financing requirements, and general economic, industry, and capital markets conditions; the ability to secure and maintain strategic partnerships or other transactions; and the ability to realize any economic benefit from the prior ANDA transaction. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, PharmaTher undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Additional risk factors are described in the Company’s MD&A for the three and six months ended November 30, 2025, dated January 29, 2026, available on SEDAR+.
 
This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

​U.S. regulatory momentum in psychedelics and peptides could open new commercial opportunities for PharmaTher’s PatchPrint™ automated manufacturing platform and PharmaPatch™ product platform as an attractive solution for compounding pharmacies, hospitals, research institutions, and commercial partners

TORONTO, ON — April 20, 2026 — PharmaTher Holdings Ltd. (OTCQB: PHRRF; CSE: PHRM) (“PharmaTher” or the “Company”), a specialty pharmaceutical company focused on microneedle patch technologies, believes it is well-positioned to benefit from two major U.S. regulatory developments: growing federal support for psychedelic medicine and advancing efforts to restore broader compounding access for select therapeutic peptides.

Two major U.S. federal shifts have created a compelling commercial opening for the Company’s microneedle patch solutions:

1. Executive Order on Psychedelics: President Trump has signed the "Accelerating Medical Treatments for Serious Mental Illness" order. This mandates federal agencies to fast-track research, approvals, and patient access to psychedelic medicines.
2. Peptide Reclassification: The FDA and HHS are moving to reclassify therapeutic peptides back to Category 1. This shift allows compounding pharmacies to once again produce these in-demand treatments, with a critical FDA advisory meeting set for July 23–24, 2026.

A Commercial Opportunity Taking Shape
 
PharmaTher believes growing U.S. regulatory momentum in psychedelics and therapeutic peptides could create a meaningful commercial opportunity for the Company. With PatchPrint™ as its automated microneedle patch manufacturing platform and PharmaPatch™ as its microneedle patch product platform, PharmaTher believes it has built an early position in two emerging high-value markets. The Company has previously reported positive PharmaPatch™ research results with psilocybin, LSD, DMT, and MDMA, completed an IND-enabling pharmacokinetic and tolerability study for its ketamine patch, and identified BPC-157, GHK-Cu, TB-500, and KPV as peptide candidates, supported by U.S. provisional patent application No. 64/034,315. PharmaTher believes that as psychedelic therapies advance and peptide compounding potentially expands, demand could grow for more precise, convenient, and patient-friendly delivery options such as microneedle patches.
 
“We believe the regulatory environment is beginning to open in both psychedelics and peptides, and we have already positioned the Company with PatchPrint™ and PharmaPatch™,” said Fabio Chianelli, Chief Executive Officer of PharmaTher. “As momentum builds in both markets, we see a meaningful opportunity to offer practical, patient-friendly, and differentiated microneedle patch solutions.”
 
The Commercial Opportunity for PatchPrint™

PatchPrint™ is PharmaTher’s proprietary automated tabletop microneedle patch 3D printer, covered by U.S. provisional patent application No. 64/015,408. The platform is being developed as a compact, end-to-end system that integrates dispensing, drying, demolding, and packaging into a single unit.

PharmaTher believes PatchPrint™ could be an attractive solution for 503A and 503B compounding pharmacies, hospitals, research institutions, and commercial partners seeking on-demand, small-footprint microneedle patch manufacturing.
​
The Company also sees PatchPrint™ as a potential driver of future revenue through system placements, formulation supply, consumables, service agreements, licensing, co-development, and contract manufacturing relationships.

Figure 1. Prototype rendering of PatchPrint™, PharmaTher’s automated tabletop microneedle patch production platform designed for end-to-end manufacturing.
 
The Advantage of Microneedle Patches over Oral, Injectable, and Traditional Patch Delivery

PharmaTher believes microneedle patches offer important advantages over traditional delivery methods. Compared with oral delivery, they may avoid gastrointestinal degradation and first-pass metabolism. Compared with injections, they may improve convenience, reduce needle use, and support self-administration. Compared with traditional transdermal patches, microneedle patches may enable the delivery of a broader range of molecules, including peptides and other compounds that do not easily cross the skin barrier on their own.
​
The Company believes these advantages could make microneedle patches especially relevant in both peptides and psychedelics, where dosing control, patient experience, and ease of use are important.

​Figure 2. Representative image of PharmaTher’s PharmaPatch™ ketamine microneedle patch and close-up of the microneedle array.

A Platform Strategy Built for Growth

PharmaTher believes its strategy stands out because it combines three key elements in one integrated platform:

1. PatchPrint™ as the manufacturing platform,
2. PharmaPatch™ as the product platform, and
3. Formulation IP to help protect and expand future commercial opportunities.

The Company believes it is positioned at an early stage of two potentially important market shifts: broader medical adoption of psychedelics and renewed compounding access for therapeutic peptides.

The Company notes that there can be no assurance as to the outcome, timing or scope of any regulatory change. However, PharmaTher believes the current policy direction is encouraging and supports continued execution of its peptide and psychedelic focused strategy.
 
About PatchPrint™
 
PatchPrint™ is PharmaTher’s proprietary automated tabletop microneedle patch manufacturing platform, covered by U.S. provisional patent application No. 64/015,408, and designed as a compact end-to-end system for on-demand patch production. PatchPrint™ could make microneedle patch manufacturing more practical for compounding pharmacies, hospitals, research institutions, and commercial partners by combining multiple production steps into one platform and supporting personalized, small-footprint manufacturing across peptides, psychedelics, biologics, and other high-value applications. The Company believes PatchPrint™ strengthens its long-term strategic position by supporting both proprietary PharmaPatch™ programs and other formulations developed for partners within a more integrated platform ecosystem.

About PharmaTher Holdings Ltd.
 
PharmaTher Holdings Ltd. (OTCQB: PHRRF; CSE: PHRM) is a specialty pharmaceutical company focused on developing, acquiring, and commercializing pharmaceutical products and enabling technologies. The Company is advancing microneedle patch solutions through its PatchPrint™ automated manufacturing platform and PharmaPatch™ product platform, with opportunities across peptides, psychedelics, therapeutics and other high-value applications. For more information, visit PharmaTher.com.
 
For more information about PharmaTher, please contact:
 
Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com
 
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
 
Forward-Looking Statements
 
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. Forward-looking statements in this release include, but are not limited to, statements regarding: the potential impact of U.S. regulatory developments relating to psychedelic therapies and therapeutic peptides; the potential reclassification or broader compounding access of certain peptides; the timing, outcome, or significance of any FDA, HHS, DEA, or other governmental actions, meetings, reviews, policy initiatives, or regulatory changes; the development, capabilities, commercial potential, and future deployment of PharmaTher’s PatchPrint™ and PharmaPatch™ platforms; the potential advantages, adoption, and market opportunity for microneedle patch delivery; the Company’s intellectual property strategy; the potential for future partnerships, licensing, co-development, service, formulation supply, consumables, contract manufacturing, system placements, or other revenue opportunities; and the Company’s ability to capitalize on opportunities in psychedelics, peptides, therapeutics, and other high-value applications. Forward-looking statements are often identified by words such as “believe,” “expects,” “plans,” “intends,” “may,” “could,” “would,” “should,” “anticipates,” “potential,” “opportunity,” and similar expressions. These statements are based on management’s current expectations, assumptions, and beliefs as of date of this news release and are subject to known and unknown risks, uncertainties, and other factors that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others, risks related to regulatory decisions and timelines, the outcome of advisory committee reviews, the availability and scope of compounding pathways, research and development results, product development and commercialization, intellectual property protection, manufacturing feasibility, market acceptance, competitive developments, financing requirements, strategic partnerships, and general economic, industry, and capital markets conditions. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, PharmaTher undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Additional risk factors are described in the Company’s MD&A for the three and six months ended November 30, 2025, dated January 29, 2026, available on SEDAR+.
 
This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

​Anticipated peptide reclassification could expand the addressable market for PharmaTher’s PharmaPatch™ product strategy and PatchPrint™ manufacturing platform, strengthening its position in next-generation peptide delivery

TORONTO, ON — April 16, 2026 — PharmaTher Holdings Ltd. (OTCQB: PHRRF; CSE: PHRM) (“PharmaTher” or the “Company”), a specialty pharmaceutical company focused on microneedle patch technologies and peptide-enabled product opportunities, today expressed support for recent U.S. initiatives led by U.S. Health and Human Services Secretary Robert F. Kennedy Jr. and the U.S. Food and Drug Administration (FDA) to revisit the regulatory treatment of select therapeutic peptides.

“We applaud Secretary Kennedy and the FDA for advancing a science-based, patient-centered review of the peptide compounding framework and for supporting a more practical, medically supervised pathway for selected therapeutic peptides,” said Fabio Chianelli, Chief Executive Officer of PharmaTher. “We believe this evolving policy direction could be highly value-accretive for PharmaTher, as it directly aligns with the peptide-focused strategy we have built around PharmaPatch™ and PatchPrint™. A clearer and more accessible regulatory path for peptides would be constructive for patients, prescribers and innovators, while strengthening the commercial relevance of our peptide delivery, formulation and manufacturing capabilities. As the regulatory landscape evolves, we believe PharmaTher is strategically ahead of the shift and well positioned to expand its peptide-focused opportunities.”

PharmaTher believes the current U.S. policy review, including the FDA’s planned July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee and related public comment process, could represent an important catalyst for the Company’s peptide-focused strategy. According to the FDA’s notice, the Committee is scheduled to review BPC-157-related, KPV-related, TB-500-related and MOTs-C-related bulk drug substances on July 23 for possible inclusion on the Section 503A Bulks List. PharmaTher believes this is directly relevant to its previously announced peptide strategy, as BPC-157, KPV and TB-500 are already among the peptide candidates it has identified for evaluation under PharmaPatch™. If the regulatory pathway for certain peptides becomes more accessible, the Company believes it could expand the commercial opportunity for PharmaPatch™ and strengthen the strategic relevance of PatchPrint™, its microneedle patch manufacturing platform.

Why This Matters for PharmaPatch™

PharmaTher previously announced that it is evaluating select therapeutic peptides for its PharmaPatch™ microneedle patch platform, including BPC-157, GHK-Cu, TB-500, KPV and potential combinations of those peptides. Importantly, three of the peptide categories now listed on the FDA’s July 23 agenda — BPC-157, KPV and TB-500 — are already part of PharmaTher’s previously disclosed peptide roadmap.

The Company believes this overlap strengthens the relevance of its PharmaPatch™ strategy at a time when the U.S. regulatory framework for certain peptides may be shifting. If access to these peptides broadens through lawful, medically supervised channels, PharmaTher believes a microneedle patch format could offer a differentiated delivery option focused on convenience, needle-free administration, patient adherence and future product flexibility.

Why PatchPrint™ Could Benefit

PharmaTher also believes the proposed policy shift could strengthen the commercial case for PatchPrint™, the Company’s proprietary automated tabletop microneedle patch manufacturing platform. Introduced in March 2026, PatchPrint™ is intended to support both PharmaTher’s own PharmaPatch™ pipeline and third-party opportunities across pharmaceutical companies, hospitals, pharmacies, including 503A compounding pharmacies, and other partner settings.
​
If peptide compounding and related medical use cases expand in the United States, PharmaTher believes PatchPrint™ could become increasingly relevant as a scalable platform for developing and manufacturing peptide-based microneedle patch products. The Company further believes PatchPrint™ could be particularly attractive to 503A pharmacy compounders as a potential customer segment, given its compact footprint, programmable manufacturing approach and potential to support differentiated peptide patch formulations in pharmacy environments, subject to applicable regulatory requirements.

​Adds Support to PharmaTher’s Peptide IP Strategy

On April 13, 2026, PharmaTher announced the filing of U.S. provisional patent application No. 64/034,315, titled Stabilized Peptide Compositions for Microneedle and Transdermal Delivery. The patent filing is intended to strengthen the Company’s peptide formulation capabilities for PharmaPatch™ while complementing PatchPrint™ as part of its broader commercialization strategy.

The application includes formulation approaches designed to help protect peptides during manufacturing, drying, storage and use, and includes embodiments involving BPC-157, GHK-Cu, TB-500 and KPV, as well as multi-peptide combinations. PharmaTher believes this formulation layer could become increasingly important as peptide product opportunities continue to grow.

A More Complete Peptide Strategy

PharmaTher believes the proposed peptide policy shift, if implemented as described, could materially strengthen the commercial opportunity for its peptide-focused strategy. With PharmaPatch™ as its peptide product platform, PatchPrint™ as its manufacturing platform, and a growing peptide formulation IP portfolio, the Company believes it is building an integrated position in next-generation peptide delivery.

PharmaTher believes this positions the Company to pursue multiple future growth opportunities, including proprietary product development, strategic collaborations, compounding-related opportunities and partner-facing platform deployments.
 
“This is more than a regulatory headline for PharmaTher. We view it as a potential external catalyst that supports the peptide-focused strategy we have been building,” added Mr. Chianelli. “PharmaPatch™ provides product opportunity, our peptide patent work strengthens our formulation foundation, and PatchPrint™ adds a manufacturing platform. Together, we believe these elements position PharmaTher with a more integrated platform for its next phase of peptide-focused growth.”
 
The Company notes that the FDA process remains ongoing and there can be no assurance as to the outcome, timing or scope of any regulatory change. However, PharmaTher believes the current policy direction is encouraging and supports continued execution of its peptide-focused strategy.
 
About PharmaTher Holdings Ltd.
 
PharmaTher Holdings Ltd. (OTCQB: PHRRF; CSE: PHRM) is a specialty pharmaceutical company focused on developing, acquiring, and commercializing pharmaceutical products and enabling technologies. The Company is advancing microneedle patch solutions through its PharmaPatch™ product strategy and PatchPrint™ manufacturing platform, with opportunities across therapeutics, peptides and other high-value applications. For more information, visit PharmaTher.com.
 
For more information about PharmaTher, please contact:
 
Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com
 
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
 
Forward-Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including, but not limited to, statements regarding: potential regulatory developments relating to therapeutic peptides in the United States; the timing, scope and outcome of any FDA advisory committee review, related regulatory process or potential policy change; the possible implications of any such developments for the Company’s business, strategy or market opportunities; the development, positioning and potential commercialization of PharmaPatch™ and PatchPrint™; the scope, utility or potential commercial significance of the Company’s intellectual property; and the Company’s ability to pursue or realize product, partnership, compounding-related or platform deployment opportunities. Forward-looking statements are based on management’s current expectations, assumptions and beliefs as of the date of this news release and are subject to a number of known and unknown risks, uncertainties and other factors, many of which are beyond the Company’s control, that could cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. These factors include, among others, risks relating to regulatory review and decision-making, changes in applicable laws or policies, the uncertainty of commercial development, the ability of the Company to execute its business plans, obtain or maintain intellectual property protection, secure partnerships or other opportunities, and general market, financing, scientific and economic conditions. There can be no assurance that any forward-looking statements will prove to be accurate, and readers are cautioned not to place undue reliance on such statements. Except as required by applicable law, PharmaTher undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. Except as required by applicable law, PharmaTher undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additional risk factors are described in the Company’s MD&A for the three and six months ended November 30, 2025, dated January 29, 2026, available on SEDAR+.
​
This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

​TORONTO, ON — April 13, 2026 — PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (“PharmaTher” or the “Company”), a specialty pharmaceutical company, announced it has submitted U.S. provisional patent application No. 64/034,315 to the United States Patent and Trademark Office, titled “Stabilized Peptide Compositions for Microneedle and Transdermal Delivery.” The patent filing covers formulation technologies designed to help protect peptides from degradation during manufacturing, drying, storage and use, supporting PharmaPatch™ as PharmaTher’s product strategy while complementing PatchPrint™ as its microneedle patch manufacturing platform.
 
“Peptides represent an exciting and growing category, but one of the biggest formulation challenges is maintaining their stability throughout development, manufacturing and storage,” said Fabio Chianelli, Chief Executive Officer of PharmaTher. “This patent filing is designed to support our PharmaPatch strategy by protecting formulation approaches that could make peptide microneedle patches more practical, scalable and commercially attractive. We also believe it strengthens how PharmaPatch and PatchPrint can work together, with PharmaPatch focused on product opportunities and PatchPrint focused on manufacturing.”
 
Supporting PharmaPatch™ Product Development
 
PharmaTher is advancing PharmaPatch as part of its broader microneedle patch strategy to develop patient-friendly delivery solutions. The Company believes stabilized peptide formulations could become an important part of that strategy by helping enable microneedle patches for peptides that may otherwise be difficult to formulate in a practical dried dosage form.
 
The provisional patent application is intended to support PharmaPatch by protecting compositions that may improve peptide stability, preserve biological activity, extend shelf life and improve manufacturing compatibility. PharmaTher believes this could support future in-house product programs, lifecycle expansion opportunities and potential strategic partnerships involving peptide patch products.
 
The Importance of a Peptide Microneedle Patch
 
Peptides can lose effectiveness when exposed to moisture, heat, oxidation, pH changes and other manufacturing or storage stresses. PharmaTher’s patent application is intended to address these challenges through formulations using polymers, sugars, amino acids, buffers and other stabilizing components that may help preserve peptide integrity and activity.

The application also covers layered microneedle patch designs in which the peptide can be concentrated in the microneedle tip region while the backing layer is optimized separately for strength, manufacturability and faster drying. PharmaTher believes this approach could improve peptide efficiency, reduce waste and support more practical product development. In addition, the application includes low-moisture packaging approaches intended to improve storage and handling, which may be important for future peptide patch commercialization.
 
Clear Fit with PatchPrint™
 
PharmaTher views PharmaPatch as its product strategy and PatchPrint as the manufacturing platform intended to help produce microneedle patches more efficiently and consistently. This new patent filing is designed to strengthen the formulation layer between the two.
 
In simple terms, if PharmaPatch defines what peptide patch products the Company wants to develop, and PatchPrint is intended to help make them, this patent is meant to help protect how sensitive peptide ingredients can be stabilized inside the patch. PharmaTher believes that the combination could be important in building a more complete microneedle patch platform covering product design, formulation and manufacturing.

Beyond supporting PharmaTher’s own product development and commercialization efforts, PatchPrint is designed as a small-footprint manufacturing platform that could be used in pharmaceutical companies, hospitals, compounding pharmacies and remote settings for medical countermeasures and vaccines, while enabling programmable production for a broad range of payloads, including small-molecule drugs, proteins, dietary supplements, biologics and peptides.
 
Supports Multiple Peptide Opportunities
 
The provisional patent application is intended to support a broad range of peptide categories, including metabolic peptides such as GLP-1 receptor agonists, wound-healing and regenerative peptides, cosmetic and metal-binding peptides, and anti-inflammatory or antimicrobial peptides.
 
The application also includes embodiments naming peptides such as BPC-157, GHK-Cu, TB-500 and KPV, as well as formulations that may contain combinations of two or more peptides in a single dosage form. PharmaTher believes these capabilities may help support future PharmaPatch opportunities across therapeutic, regenerative, dermatology and other peptide-focused applications.
 
Commercial Strategy
 
PharmaTher intends to continue evaluating peptide-based microneedle patch opportunities as part of its PharmaPatch commercialization strategy. The Company believes peptides may represent a meaningful opportunity because of growing interest in patient-friendly and differentiated delivery formats.
 
By expanding its formulation intellectual property, PharmaTher aims to strengthen PharmaPatch as a product platform while improving how PatchPrint may support future development and manufacturing. The Company believes this approach could enhance its long-term position in microneedle patches by supporting both the stabilization of sensitive peptide ingredients and the ability to manufacture peptide patch products more efficiently.
 
About PharmaTher Holdings Ltd.
 
PharmaTher Holdings Ltd. (OTCQB: PHRRF; CSE: PHRM) is a specialty pharmaceutical company focused on developing, acquiring, and commercializing pharmaceutical products and enabling technologies. For more information, visit PharmaTher.com.
 
For more information about PharmaTher, please contact:
 
Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com
 
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
 
Forward-Looking Statements
 
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including statements regarding the Company’s intellectual property strategy; the expected scope, value and potential benefits of U.S. provisional patent application No. 64/034,315; the potential of the disclosed stabilized peptide compositions to improve peptide stability, shelf life, handling, manufacturability or delivery performance; the advancement of PharmaPatch™ and future peptide-focused microneedle patch opportunities; the integration of peptide formulation capabilities with PatchPrint™ as a manufacturing platform; the potential applicability of the technology to peptide categories including metabolic peptides, wound-healing and regenerative peptides, cosmetic and metal-binding peptides, and anti-inflammatory or antimicrobial peptides; the potential development of microneedle patch products containing peptides such as BPC-157, GHK-Cu, TB-500 and KPV, or combinations thereof; and the potential commercial opportunity for peptide-based microneedle patch products, internal programs and strategic partnerships.
 
Forward-looking statements are based on management’s current expectations, assumptions and beliefs, including assumptions regarding the Company’s ability to protect and maintain intellectual property, develop stable peptide formulations, advance PharmaPatch™ programs, continue development of PatchPrint™, integrate formulation and manufacturing capabilities, secure technical and commercial partners, and capture market opportunities in peptide delivery and related applications.
 
These forward-looking statements are subject to a number of known and unknown risks, uncertainties and other factors, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied in such statements. Such risks and uncertainties include, without limitation, the risk that patent protection may not be obtained, maintained or provide meaningful commercial protection; that the technologies described in the provisional patent application may not perform as expected; that peptide stabilization, manufacturing or storage goals may not be achieved; that PharmaPatch™ or PatchPrint™ may not advance as currently anticipated; that product development programs may be delayed, limited or unsuccessful; that regulatory, technical, manufacturing, clinical, commercial or market adoption challenges may arise; and that anticipated market opportunities for peptide microneedle patches may not develop as expected.
 
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. Except as required by applicable law, PharmaTher undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additional risk factors are described in the Company’s MD&A for the three and six months ended November 30, 2025, dated January 29, 2026, available on SEDAR+.
 
This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

TORONTO, ON — March 3, 2026 — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF; CSE: PHRM), a specialty pharmaceutical company focused on unlocking the therapeutic potential of psychedelics and peptides, today announced a strategic initiative to expand its PharmaPatch™ microneedle patch platform into select therapeutic peptides for the U.S. market, building on the Company’s ketamine and psychedelics patch development achievements and its recent entry into GLP-1 delivery using PharmaPatch™.

“Building on our ketamine and psychedelics patch programs and our expansion into GLP-1 delivery, we are now broadening PharmaPatch™ to evaluate select peptide candidates where a needle-free, at-home patch could improve real-world use,” said Fabio Chianelli, Founder and CEO of PharmaTher.

Regulatory and Policy Discussion: Monitoring Potential Tailwinds (U.S.)

PharmaTher is monitoring the evolving U.S. policy discussion regarding certain peptides and compounding access. On a recent episode of The Joe Rogan Experience (Episode dated February 27, 2026), U.S. HHS Secretary Robert F. Kennedy Jr. discussed peptides and stated he was “very anxious” to move about 14 of the 19 peptides he referenced “back” toward being more accessible, and indicated the FDA could announce actions on a near-term timeline.

A Large and Growing U.S. Market Opportunity

Therapeutic peptides represent a rapidly expanding segment of modern medicines across multiple therapeutic areas. Grand View Research estimates the U.S. peptide therapeutics market generated approximately US$65.1 billion in 2024 and is projected to reach approximately US$160.3 billion by 2030 (14.7% CAGR).

PharmaTher believes that delivery innovation—including patient-friendly administration and differentiated pharmacokinetic profiles—can be an important value driver for peptide programs, particularly in chronic conditions where persistence and convenience matter.

Initial Peptide Candidates Under Evaluation

As part of its peptide initiative, PharmaTher is seeking to investigate PharmaPatch™ delivery feasibility for certain peptides, including:

• BPC-157
• GHK-Cu (copper tripeptide-1)
• TB-500 (Thymosin Beta-4 fragment)
• KPV (Lys-Pro-Val)
• Potential combinations of the above peptides

The Company emphasizes that these candidates are being evaluated within a staged R&D framework and that any potential future development pathways will be assessed in alignment with applicable regulatory requirements.

Value Proposition: Why a Peptide Microneedle Patch

PharmaTher’s PharmaPatch™ initiatives are designed to address real-world administration challenges by delivering medicines in a patient-friendly form factor, with the potential to support sustained exposure.

Potential advantages of a peptide microneedle patch approach (depending on the peptide and formulation) may include:

• Needle-free administration using microneedle-enhanced delivery
• At-home convenience and simplified patient experience
• Potential for controlled delivery profiles and combinations
• Support improved adherence versus conventional injection-based routines

Microneedle patch technology is widely described in the scientific literature as enabling painless self-administration compared with conventional injections, supporting its relevance to long-term therapies.

PharmaPatch™ Development Proof Points 

PharmaTher has disclosed a series of PharmaPatch™ research and development achievements across ketamine and multiple psychedelics, including:
 

• Ketamine Patch: completion of an IND-enabling pharmacokinetic and tolerability study under GLP compliance in minipigs; reported extended delivery over 40 hours and favorable tolerability observations.1
  
• Psilocybin: completion of a microneedle patch research study demonstrating compatibility/suitability for psilocybin delivery and supporting future regulatory planning.2
  
• LSD: completion of a microneedle patch research study with successful fabrication, ex vivo skin insertion assessment, and multi-day release observations supporting potential for modified release profiles.3
  
• DMT: successful completion of a research study evaluating PharmaPatch™ for N,N-dimethyltryptamine (DMT) delivery, including fabrication/characterization, ex vivo skin insertion assessment, and multi-day release observations.4
  
• MDMA: disclosed microneedle patch research collaborations and platform development history that include MDMA as a target psychedelic for patch delivery.

Development Plan and Intellectual Property Strategy

PharmaTher plans to advance its peptide-focused PharmaPatch™ initiative through staged feasibility and development activities, which may include:

1. Clinical evaluation
2. Manufacturing and scale-up assessment
3. Intellectual property filings arising from peptide delivery work

PharmaTher cautions that policy discussions and timelines related to peptides are subject to change, and that any development plans will be pursued in alignment with applicable U.S. regulatory requirements.

PharmaPatch™: Proprietary Microneedle Delivery Platform

PharmaPatch™ is a proprietary microneedle-enhanced delivery system designed to provide an efficient, minimally invasive, and potentially painless method for delivering drug candidates, including psychedelics, peptides, and other medicines. The microneedle patch technology is based on a novel biocompatible and biodegradable gelatin methacryloyl (“GelMA”) material intended to enable delivery of both water-soluble and water-insoluble compounds with customizable release profiles. The GelMA-based microneedle array is designed to penetrate the stratum corneum (outer layer of the skin) and supports flexible drug-loading capacity, including potential combinations, microdosing, and controlled-release delivery. Microneedles are widely considered a promising approach to achieve systemic drug exposure via transdermal delivery while potentially avoiding absorption limitations and first-pass metabolism associated with oral administration. PharmaPatch™ is also intended to support at-home self-administration and incorporates anti-tampering and anti-abuse features. The Company has completed research studies demonstrating PharmaPatch™ feasibility for delivering psychedelic compounds.

The proposed PharmaPatch™ products are strictly for research use only and are not intended for human cosmetic or therapeutic applications at this time. The product candidates described herein are investigational. Safety and efficacy have not been established, and they have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority.

About PharmaTher Holdings Ltd.
 
PharmaTher Holdings Ltd. (OTCQB: PHRRF; CSE: PHRM) is a specialty pharmaceutical company focused on developing, acquiring, and commercializing pharmaceutical products and enabling technologies. For more information, visit PharmaTher.com.

For more information about PharmaTher, please contact:

Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary and Forward Looking Statements

This news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities laws (collectively, “forward-looking information”). Forward-looking information includes, but is not limited to, statements regarding: the Company’s strategic initiative to expand its PharmaPatch™ microneedle patch platform into select therapeutic peptides for the U.S. market; the Company’s plans to investigate the feasibility of delivering certain peptides (including BPC-157, GHK-Cu (copper tripeptide-1), TB-500 (Thymosin Beta-4 fragment), KPV) and potential combinations thereof; the anticipated advantages, potential performance characteristics, and potential value proposition of PharmaPatch™ for peptide delivery (including potential convenience, adherence, and controlled delivery profiles); the Company’s staged research and development plans, timelines, and expected next steps, including formulation work, patch-engineering optimization, preclinical evaluation, manufacturing and scale-up assessment, and intellectual property strategy; the potential size, growth, and commercial opportunity of peptide therapeutics markets; the Company’s ability to pursue and realize strategic partnerships, collaborations, or other transactions; and the Company’s expectations regarding regulatory and policy developments in the United States, including any potential changes to the regulatory status, oversight, or accessibility of certain peptides and the timing of any related regulatory announcements.

Forward-looking information is based on management’s current expectations and assumptions, including, without limitation, assumptions regarding: the technical feasibility of formulating and delivering peptides through the PharmaPatch™ platform; the availability and performance of third-party service providers and suppliers; the ability to protect and enforce intellectual property; the availability of capital and resources to advance development activities; the relevance and reliability of third-party market data and estimates; and the evolution of regulatory, policy, and enforcement priorities in the United States and other jurisdictions. Forward-looking information is subject to a number of known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, but are not limited to: scientific and technical risks inherent in early-stage research and development; formulation and stability challenges; uncertainty in achieving desired delivery, pharmacokinetic, or performance outcomes; the risk that preclinical results may not be predictive of future results; manufacturing development and scale-up risks; quality and supply chain constraints; reliance on third parties; intellectual property risks, including the ability to obtain, maintain, and enforce patent and other protections and the risk of third-party infringement claims; competition and technological change; market acceptance and adoption risks; changes in applicable laws, regulations, policies, and regulatory interpretations, including those related to peptides, compounding, and FDA oversight; and general economic, market, financing, and geopolitical conditions.

Readers are cautioned not to place undue reliance on forward-looking information. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. The forward-looking information contained in this news release is made as of the date hereof and is expressly qualified by this cautionary statement. Additional risk factors are described under the heading “Risk Factors” in the Company’s management’s discussion and analysis for the three and six months ended November 30, 2025, dated January 29, 2026, available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.
Footnotes / Sources

1. PharmaTher Holdings Ltd. “PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with Ketamine Patch” (Sept. 7, 2022). PharmaTher Holdings Ltd. Ketamine
   
2. PharmaTher Holdings Ltd. “PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch” (Nov. 11, 2021). PharmaTher Holdings Ltd. Psilocybin
   
3. PharmaTher Holdings Ltd. “PharmaTher Announces Positive Research Results for LSD Microneedle Patch” (Dec. 14, 2021). PharmaTher Holdings Ltd. LSD
   
4. PharmaTher Holdings Ltd. “PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics” (July 18, 2023). PharmaTher Holdings Ltd. DMT

TORONTO, ON — February 2, 2026 — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM; OTCQB: PHRRF), a specialty pharmaceutical company, today announced a new strategic initiative to pursue Health Canada approval for generic semaglutide in Canada and, subject to regulatory approval, its commercialization. Semaglutide is the active ingredient in Ozempic® and Wegovy®. The initiative builds on PharmaTher’s demonstrated regulatory and partnering execution, including its U.S. FDA approval of ketamine and the monetization of U.S. rights with potential proceeds exceeding US$25 million.
 
Canada Opens as an Early Major Market for Generic Semaglutide
 
In January 2026, regulatory exclusivity for semaglutide in Canada expired, creating a pathway for regulated generic competition and drawing global attention to Canada as an early major market for generic semaglutide.
 
Ozempic® was estimated to have generated approximately C$2.9 billion in Canadian sales in 2025 (Source: IQVIA Canada). Industry estimates suggest the broader GLP-1 receptor agonist opportunity in Canada could grow to approximately US$6.5 billion by 2033 (Source: Grand View Research), reflecting increasing demand and broader adoption.
 
PharmaTher’s Plan: Speed-to-Market, Reliable Supply, Broad Dose Coverage
 
PharmaTher’s initiative is designed to position the Company among the early suppliers of generic semaglutide in Canada following regulatory approval, supported by:
 

• Clear near-term milestone: pursuing Health Canada approval in 2026
• Broad dose coverage across the treatment journey (0.25 mg to 2.4 mg)
• Sterile injectable manufacturing strategy: leveraging a cost-effective, high-quality commercial sterile injectable manufacturer with facilities audited by regulatory health authorities
• Platform-building focus: scaling injectable capabilities to support long-term semaglutide supply reliability and enable future global partnering opportunities

 
“Canada’s semaglutide market is entering a pivotal transition: demand is growing, and affordable access and reliable supply will matter,” said Fabio Chianelli, Founder, Chairman and CEO of PharmaTher. “We’ve already proven we can execute on FDA approval of injectable drugs and structure a meaningful pharma partnership in ketamine. We are now applying that same execution playbook to pursue Health Canada approval for generic semaglutide and build a scalable sterile injectable platform for the obesity and diabetes market.”
 
Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Use of these trademarks is for identification purposes only and does not imply affiliation, sponsorship, or endorsement.
 
About PharmaTher Holdings Ltd.
 
PharmaTher Holdings Ltd. (CSE: PHRM; OTCQB: PHRRF) is a specialty pharmaceutical company focused on developing, acquiring, and commercializing pharmaceutical products and enabling technologies. For more information, visit PharmaTher.com.

For more information about PharmaTher, please contact:

Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary and Forward Looking Statements

This news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws (collectively, “forward-looking information”). Forward-looking information may include statements regarding, among other things: the timing and outcome of regulatory submissions and reviews (including potential Health Canada approval and the timing of any commercial launch); the Company’s ability to secure, maintain and scale manufacturing, supply, logistics and distribution arrangements; anticipated market size, pricing dynamics and demand and broader adoption for semaglutide products in Canada; and the Company’s ability to enter into or realize the benefits of strategic partnerships, collaborations or other transactions. Forward-looking information is based on management’s current expectations and assumptions and is subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking information, including risks related to regulatory processes and timelines, manufacturing and supply constraints, competition, market acceptance, pricing and reimbursement, and general economic and market conditions. Readers are cautioned not to place undue reliance on forward-looking information. Except as required by law, PharmaTher undertakes no obligation to update any forward-looking information, whether as a result of new information, future events or otherwise. Other risk factors are described under the heading “Risk Factors” in the Company’s management’s discussion and analysis for the three and six months ended November 30, 2025, dated January 29, 2026, available under the Company’s profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and the Company does not undertake any obligation to update or revise such information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein.
This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

TORONTO — January 14, 2026 — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF; CSE: PHRM), a specialty pharmaceutical company focused on unlocking the therapeutic potential of ketamine, psychedelics, and GLP-1 drugs for neuropsychiatric and obesity disorders, today announced a new strategic initiative to expand its PharmaPatch™ microneedle patch platform into GLP-1 therapies for the potential treatment of obesity.

PharmaTher’s decision to enter the obesity market builds on the Company’s successful development progress with its ketamine and multiple psychedelic compounds patch programs, including pre-IND-enabling work and published research demonstrating controlled, sustained delivery and flexible patch design principles.1-6 

“PharmaTher built PharmaPatch™ to solve real-world administration challenges delivering medicines in a patient-friendly form factor with the potential to support sustained drug exposure,” said Fabio Chianelli, Founder and CEO of PharmaTher. “After advancing our ketamine and multiple psychedelic patch programs, we are now applying that platform to one of the largest and fastest-growing opportunities in global healthcare: GLP-1 therapy for obesity. Our objective is to develop a needle-free, at-home microneedle patch designed to support long-acting delivery—potentially up to one month from a single patch application.”

Leveraging Ketamine and Psychedelic Patch Progress to Accelerate Platform Expansion

PharmaTher’s ketamine and psychedelic patch programs have been designed to enable controlled and sustained delivery and to reduce administration burden, with reported results supporting extended delivery, tolerability, and flexible dosing through patch size and drug loading parameters.1-6 The Company believes these platform capabilities are directly relevant to GLP-1 therapies, where long-term adherence and convenience are important drivers of real-world effectiveness.

A Large U.S. Market Opportunity in Obesity and Diabetes

Obesity represents major and growing public health challenges in the United States. CDC reports that more than 2 in 5 U.S. adults have obesity.7 Industry forecasts underscore the scale of the commercial opportunity. Grand View Research estimates the U.S. obesity treatment market generated approximately $11.2 billion in 2024 and may reach approximately $48.5 billion by 2030, driven in part by GLP-1 therapies.8

Potential Benefits of a GLP-1 Microneedle Patch

PharmaTher’s GLP-1 PharmaPatch™ initiative is designed to explore a differentiated delivery approach with the potential to offer several patient and product advantages versus conventional injection-based regimens, including:

• Needle-free administration using microneedle-enhanced intradermal delivery
  
• At-home convenience and a simplified patient experience
  
• Sustained, controlled delivery profile intended to support consistent drug exposure
  
• Flexible dosing potential through patch design variables (e.g., surface area, application time, drug loading), consistent with principles demonstrated in the Company’s prior patch development work2,3
  
• Targeting extended-duration delivery—potentially up to one month with a single patch application (subject to formulation optimization, preclinical results, and clinical validation)

Development Plan and Intellectual Property Strategy

PharmaTher plans to progress the GLP-1 PharmaPatch™ initiative through feasibility work and preclinical evaluation. The Company is finalizing a patent application covering innovations arising from this program and expects to file the application later this month.

About PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a specialty pharmaceutical company focused on acquiring and advancing assets that can be efficiently monetized to generate revenue, equity value, and strategic partnerships. The Company currently manages three assets: (i) KETARx™ portfolio of ketamine drugs and data; (ii) PharmaPatch™ microneedle patch platform delivering ketamine, psychedelics, and GLP-1 drugs for neuropsychiatric and obesity disorders; and (iii) a 49% equity interest in Sairiyo Therapeutics Inc., which is focused on a patented oral formulation of cepharanthine for infectious diseases and cancer. For more information, visit PharmaTher.com.

For more information about PharmaTher, please contact:

Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary and Forward Looking Statements
This press release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws. Forward-looking information includes statements regarding the Company’s GLP-1 PharmaPatch™ initiative; the potential benefits, dosing duration (including potential monthly dosing), and performance characteristics of a microneedle patch; development plans; market opportunity; and potential strategic or commercial outcomes. Forward-looking information is based on assumptions and is subject to risks, uncertainties, and other factors that could cause actual results to differ materially. Readers should not place undue reliance on forward-looking information. PharmaTher undertakes no obligation to update forward-looking information except as required by law. Other risk factors are described under the heading “Risk Factors” in the Company’s management’s discussion and analysis for the three months ended August 31, 2025, dated October 24, 2025, available under the Company’s profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and the Company does not undertake any obligation to update or revise such information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein.
This news release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

Footnotes / Sources

1.     PharmaTher Holdings Ltd. “PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA-Approved IV Ketamine Aligned with FDA’s CNPV National Priority Initiative” (Aug. 27, 2025). PharmaTher Holdings Ltd. Ketamine
2.     PharmaTher Holdings Ltd. “PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch” (June 29, 2022). PharmaTher Holdings Ltd. Ketamine
3.     PharmaTher Holdings Ltd. “PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with Ketamine Patch” (Sept. 7, 2022). PharmaTher Holdings Ltd. Ketamine
4.     PharmaTher Holdings Ltd. “PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch” (Nov. 11, 2021). PharmaTher Holdings Ltd. Psilocybin
5.     PharmaTher Holdings Ltd. “PharmaTher Announces Positive Research Results for LSD Microneedle Patch” (Dec. 14, 2021). PharmaTher Holdings Ltd. LSD
6.     PharmaTher Holdings Ltd. “PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics” (July 18, 2023). PharmaTher Holdings Ltd. DMT
7.     U.S. Centers for Disease Control and Prevention (CDC). “Adult Obesity Facts” (May 14, 2024). CDC
8.     Grand View Research. “U.S. Obesity Treatment Market Size & Outlook, 2025–2030” (market revenue estimates for 2024 and 2030). Grand View Research